Importantly, this therapy can reverse the tumor immunosuppressive microenvironment by counteracting apoptosis-mediated inactivation of pDCs, reducing the percentages of Tregs and MDSCs, and facilitating the activation of both NK and CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.